Search Results - "Pezalla, Edmund"

Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation— Quality and Cost Implications by Desai, Nihar R., MD, MPH, Krumme, Alexis A., MS, Schneeweiss, Sebastian, MD, ScD, Shrank, William H., MD, MSHS, Brill, Gregory, MS, Pezalla, Edmund J., MD, MPH, Spettell, Claire M., PhD, Brennan, Troyen A., MD, JD, MPH, Matlin, Olga S., PhD, Avorn, Jerry, MD, Choudhry, Niteesh K., MD, PhD

“…Abstract Background Dabigatran, rivaroxaban, and apixaban have been approved for use in patients with atrial fibrillation based upon randomized trials…”
Get full text

Payer view of personalized medicine by Pezalla, Edmund J

“…The process and methods used by payers when evaluating coverage of personalized medicine testing are described. Personalized medicine encompasses a number of…”
Get full text

ISPOR’s Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers by Solow, Brian, Pezalla, Edmund J.

“…An interview with Brian Solow, chief medical officer of Optum, and Edmund J. Pezalla, chief executive officer of Enlightenment Bioconsult LLC, is presented…”
Get full text

Secular trends in opioid prescribing in the USA by Pezalla, Edmund J, Rosen, David, Erensen, Jennifer G, Haddox, J David, Mayne, Tracy J

“…Opioid abuse and misuse in the USA is a public health crisis. The use of prescription opioid analgesics increased substantially from 2002 through 2010, then…”
Get full text

Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications: A Cohort Study by Lauffenburger, Julie C, Shrank, William H, Bitton, Asaf, Franklin, Jessica M, Glynn, Robert J, Krumme, Alexis A, Matlin, Olga S, Pezalla, Edmund J, Spettell, Claire M, Brill, Gregory, Choudhry, Niteesh K

“…Despite the widespread adoption of patient-centered medical homes into primary care practice, the evidence supporting their effect on health care outcomes has…”
Get full text

Initial Assessment of Clinical Impact of a Drug Interaction Between Clopidogrel and Proton Pump Inhibitors by Pezalla, Edmund, MD, MPH, Day, David, MS, RPh, Pulliadath, Indira, MBA

“…Control (Clopidogrel, No PPI) Low PPI Exposure High PPI Exposure Members with all identified risk factors, n 384 90 536 Age (yrs) 58.24±4.68 58.32±5.79…”
Get full text

Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study by Berkowitz, Seth A, Krumme, Alexis A, Avorn, Jerry, Brennan, Troyen, Matlin, Olga S, Spettell, Claire M, Pezalla, Edmund J, Brill, Gregory, Shrank, William H, Choudhry, Niteesh K

“…Although many classes of oral glucose-lowering medications have been approved for use, little comparative effectiveness evidence exists to guide initial…”
Get more information

Advancing Value Assessment in the United States: A Multistakeholder Perspective by Sorenson, Corinna, MPH, MHSA, PhD, Lavezzari, Gabriela, PhD, MBA, Daniel, Gregory, MPH, MS, PhD, Burkholder, Randy, BA, Boutin, Marc, JD, Pezalla, Edmund, MD, MPH, Sanders, Gillian, PhD, McClellan, Mark, MD, PhD

“…Abstract Rising costs without perceived proportional improvements in quality and outcomes have motivated fundamental shifts in health care delivery and payment…”
Get full text

Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget by Kapoor, Ritika, Standaert, Baudouin, Pezalla, Edmund J, Demarteau, Nadia, Sutton, Kelly, Tichy, Eszter, Bungey, George, Arnetorp, Sofie, Bergenheim, Klas, Darroch-Thompson, Duncan, Meeraus, Wilhelmine, Okumura, Lucas M, Tiene de Carvalho Yokota, Renata, Gani, Ray, Nolan, Terry

“…Healthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A…”
Get full text

The Effect of a Pediatric Rare Disease on Subscriber Retention Rates for Commercial Health Insurers in the United States by Kuester, Melanie K, Jackson, E Anne, Runyan, Brenda M, Pezalla, Edmund J, Nussbaum, Samuel R

“…The advent of personalized medicine creates opportunities for regenerative therapies to deliver extended clinical benefit from a single administration…”
Get full text

Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014 by Sparks, Jeffrey A., Krumme, Alexis A., Shrank, William H., Matlin, Olga S., Brill, Gregory, Pezalla, Edmund J., Choudhry, Niteesh K., Solomon, Daniel H.

“…Objective Several trials suggest that triple therapy (methotrexate, sulfasalazine, and hydroxychloroquine) and biologic disease‐modifying antirheumatic drugs…”
Get full text

Considerations for the optimal use of immunoglobulin by Navarro, Robert P, Ballow, Mark, Fenrick, Beckie, Pezalla, Edmund J

“…Immunoglobulins are large Y-shaped proteins produced by B-cells and plasma cells that are used by the immune system to identify and neutralize foreign objects…”
Get full text

Practical perspectives on the management of overweight and obesity by Gregory, Robert S, Handelsman, Yehuda, Pezalla, Edmund J, Pikelny, Dan

“…The prevalence of obesity, defined as a body mass index of 30 or more, has reached epidemic proportions in the United States. Obesity is associated with an…”
Get full text

Genomic testing in oncology to improve clinical outcomes while optimizing utilization: the evolution of diagnostic testing by Collymore, David C, Kobilis, Shaunna L, Lundquist, Thomas G, McGivney, William T, Pezalla, Edmund J, Poage, Wendy

“…Cancer care is costly, particularly when chemotherapy and its supportive costs are considered. Yet, chemotherapy is not the right course for every patient…”
Get full text

Research to real-world application: experts weigh in on the underuse of anticoagulants by Berger, Jan, Balfour, 3rd, Donald C, Biskupiak, Joseph E, Dunn, Jeffrey, Liotta, Dennis B, Merli, Geno J, Pezalla, Edmund J, Shaya, Fadia T, Villanueva, Tomás

“…Although numerous studies have shown that anticoagulants can reduce the risk of stroke and thromboembolic events in patients with nonvalvular atrial…”
Get full text

Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system by Desai, Mehul, Kenney, James, Pezalla, Edmund

“…Existing healthcare systems face finite resource allocation and budgetary constraints, resulting in a substantial need for innovative solutions to enhance…”
Get full text

Evaluating Unmet Needs in Large-Volume Subcutaneous Drug Delivery: US Payer Perspectives on a Novel, Large-Volume On-Body Delivery System by Desai, Mehul, Kenney, James, Pezalla, Edmund

“…This research sought to evaluate payer perspectives around OBDS's through semi-structured interviews with 17 US payers representing approximately 227 million…”
Get more information

F3‐01‐04: PANEL DISCUSSION by Kalafatis, Chris, Pezalla, Edmund J., Rentz, Dorene M., Scheltens, Philip

Get full text

PANEL DISCUSSION by Kalafatis, Chris, Pezalla, Edmund J., Rentz, Dorene M., Scheltens, Philip

Get full text

Health insurance coverage and switching among people with hemophilia A in the United States by He, Chunla, Hinds, David, Pezalla, Edmund, Cheng, Dunlei, Chen, Er, Sammon, Joshua, Solari, Paul G, Recht, Michael

“…Hemophilia A (HA) is marked by substantial economic burden, including costs of ongoing treatment, increased monitoring, bleed events, and other health care…”
Get full text